רווח תפעולי לפני ניכוי פחת: palatin.com (PTN)

Palatin Technologies revenues are based on the sale of women's health products and ophthalmological tests. This EBITDA chart visualizes the cash flow, where 0.00 becomes the new value of the metric. However, weak demand and risks in dermatology undermine stability. Limited pricing power for Vyleesi due to insurance limits forces the company to apply significant discounts for sales.

This indicator measures net cash flow from operating activities before taxes and interest payments, allowing for an assessment of the business's actual ability to generate profit. By analyzing the consolidated EBITDA figure, an investor can compare the operating efficiency of Palatin Technologies (PTN) with the commercial success of the drug Vyleesi and the monetization potential of peptide developments through strategic partnerships.